Electroprocessed Fibrin-Based Matrices and Tissues

• US 20100310658A1
• Filed: 06/08/2010
• Published: 12/09/2010
• Est. Priority Date: 02/25/1999
• Status: Abandoned Application

• Current Assignee: David G. Simpson, Gary E. Wnek, Gary L. Bowlin, Marcus E. Carr Jr, Philippe Lam
• Original Assignee: David G. Simpson, Gary E. Wnek, Gary L. Bowlin, Marcus E. Carr Jr, Philippe Lam
• Inventors: Lam, Philippe, Simpson, David G., Bowlin, Gary L., Wnek, Gary E., Carr, Marcus E. JR.
• Application Number:
  US12/796,207
• Publication Number:
  US 20100310658A1
• Time in Patent Office: Days
• US Class Current: 424/484
• CPC Class Codes: A61K 2035/126 Immunoprotecting barriers, e.g. jackets, diffusion chambers
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61L 15/32 Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin A61L15/225 takes precedence
• CPC Class Codes: A61L 2400/04 Materials for stopping bleeding
• CPC Class Codes: A61L 27/225 Fibrin; Fibrinogen
• CPC Class Codes: A61L 27/24 Collagen
• CPC Class Codes: A61L 27/26 Mixtures of macromolecular compounds
• CPC Class Codes: A61L 27/38 containing added animal cells organs or tissue containing native cells A61L27/36
• CPC Class Codes: A61L 31/041 Mixtures of macromolecular compounds
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: B29C 41/006 using an electrostatic field for applying the material
• CPC Class Codes: C07K 14/75 Fibrinogen
• CPC Class Codes: C07K 14/78 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• CPC Class Codes: C08L 89/00 Compositions of proteins; Compositions of derivatives thereof foodstuff preparations A23J3/00
• CPC Class Codes: C12N 2503/00 Use of cells in diagnostics
• CPC Class Codes: C12N 2510/00 Genetically modified cells
• CPC Class Codes: C12N 2533/40 Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
• CPC Class Codes: C12N 2533/54 Collagen; Gelatin
• CPC Class Codes: C12N 2533/56 : Fibrin; Thrombin
• CPC Class Codes: C12N 5/0012 : Cell encapsulation
• CPC Class Codes: C12N 5/0062 : General methods for three-dimensional culture
• CPC Class Codes: C12N 5/0068 : General culture methods using substrates for specific animal cell type C12N5/06
• CPC Class Codes: C12N 5/0622 : Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells

Abstract

The invention is directed to formation and use of electroprocessed fibrin as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed fibrin may also be combined with other molecules in order to deliver the molecules to the site of application or implantation of the electroprocessed fibrin. The fibrin or fibrin/cell suspension is electrodeposited onto a substrite to form the tissues and organs.

Claims

1. Electroprocessed fibrin.

2. The electroprocessed fibrin of claim 1, in a matrix.

3. The electroprocessed fibrin matrix of claim 2, further comprising cells.

4. The electroprocessed fibrin matrix of claim 2, further comprising one or more substances.

5. The electroprocessed fibrin matrix of claim 4, wherein the one or more substances is a growth factor, differentiation inducer, anti-oxidant, vitamin, hormone, nucleic acid, drug, peptide, nucleic acid, emollient, humectant, conditioner or cosmetic

6. An engineered tissue comprising the electroprocessed fibrin matrix of claim 2 and cells.

7. The engineered tissue of claim 6, further comprising one or more substances.

8. The engineered tissue of claim 6, wherein the cells are stem cells or differentiated cells.

9. A method of delivering a substance to a desired location comprising;

adding substance to the electroprocessed fibrin of claim 1; and

,

placing the electroprocessed fibrin containing the substance in the desired location.

10. A method of delivering a substance to a desired location comprising;

adding substance to the electroprocessed fibrin matrix of claim 2; and

,

placing the electroprocessed fibrin matrix containing the substance in the desired location.

11. A method of treating a wound, comprising applying the electroprocessed fibrin of claim 1 to the wound.

12. A method of treating a wound, comprising applying the electroprocessed fibrin matrix of claim 2 to the wound.

13. A method of providing hemostasis, comprising applying the electroprocessed fibrin of claim 1 to a site of bleeding.

14. A method of providing hemostasis, comprising applying the electroprocessed fibrin matrix of claim 2 to a site of bleeding.

15. A method of evaluating a biological response of a cell to a substance, comprising:

applying the substance to the electroprocessed fibrin matrix and cells of claim 3; and

,

evaluating the biological response of the cell.

16. The method of claim 15, wherein the cell is a cancer cell.

17. A method of manufacturing the electroprocessed fibrin of claim 1, comprising:

electrodepositing one or more electrically-charged solutions comprising fibrin or molecules capable of forming fibrin onto a grounded target substrate under conditions effective to electrodeposit fibrin or molecules capable of forming fibrin on said substrate to form the electroprocessed fibrin.

18. A method of manufacturing the electroprocessed fibrin matrix of claim 2, comprising:

electrodepositing one or more electrically-charged solutions comprising fibrin or molecules capable of forming fibrin onto a grounded target substrate under conditions effective to electrodeposit fibrin or molecules capable of forming fibrin on said substrate to form the electroprocessed fibrin matrix.

19. A method of manufacturing the engineered tissue of claim 6, comprising:

electrodepositing one or more electrically-charged solutions comprising fibrin or molecules capable of forming fibrin, and cells, onto a grounded target substrate under conditions effective to deposit the electroprocessed fibrin or molecules capable of forming fibrin and the cells onto the substrate.

20. A method of manufacturing the engineered tissue of claim 6, comprising:

electrodepositing one or more electrically-charged solutions comprising fibrin or molecules capable of forming fibrin onto a grounded target substrate under conditions effective to deposit the electroprocessed fibrin or molecules capable of forming fibrin; and

,

applying cells onto the substrate or into a stream of the electroprocessed fibrin or molecules capable of forming fibrin, wherein the stream is located between the grounded target substrate and the solutions.

21. An electroprocessed fibrin matrix.

22. An engineered tissue comprising an electroprocessed fibrin matrix and cells.